Loofman is out makin' Jugs!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Imo, any partner/buyout will be a confirmation that Bavimaxitub is a valuable platform. If this becomes the case, I believe it will happen sooner than later. I also believe the value at buyout or financial partnership will be more than some expect, but much less than its true potential. I believe at such event the offering may bring somewhere between $3 - $6 per share in valuation. If those who believe in higher valuations want more, they will need to roll their investment into the partnering/buying company and take that chance for further upside.
Imo, If Peregrine decides not to aggressively court and work with promising suitors, their days will be gravely numbered!
Jmo
Loofman
Yes...so now I'm only down 67% on paper! I'll sleep better tonight. Lol
Local News story on cancer treatment
Louisville doctor says breakthrough treatment could wipe out cancer in a decade
LOUISVILLE, Ky. (WDRB) -- Imagine cancer being completely wiped out. The deputy director of Louisville's James Graham Brown Cancer Center says it could happen in the next decade.
There's a new breakthrough that's sparking the hope and it's already saving lives.
A simple thing like a walk with her husband has become precious for Lauren Cordy. A year ago, the 32-year-old from Jeffersonville had just gotten engaged and seemed to have her entire life ahead of her, when she was dealt a very bad hand. She found out her melanoma, or skin cancer, diagnosed about a year earlier wasn't responding to her latest round of treatment.
"After, I think it was two or three months, we did a scan and found out it had spread, and it spread to my lung and my liver," Cordy explained.
Lauren had stage 4 melanoma -- a virtual death sentence.
"I thought, 'I'm early 30s, you know I don't have kids yet. I still have the rest of my life to live. Why me?' Why me, exactly," she said.
Then Lauren was given the newly-approved drug Keytruda, the latest weapon in what's seen as the biggest breakthrough in cancer treatment ever, called immuno-therapy. It allows immune cells, or T-cells, to hunt down and devour the cancer cells.
"With immune therapies, it turns out you're just engendering the immune system," James Graham Brown Cancer Center's Dr. Jason Chesney said. "You're training it to get activated against the cancer and a lot of the immune therapies we use, we don't have to continue. We can give them for three or four months, and then stop and watch the patient."
After just three months, Cordy's tumors were shrinking. After six months, she was cancer-free.
"Officially in remission since the middle of September," Cordy said. "Right after I got married I found out. So, September was a good month, yes."
It's the same story for 51-year-old Germantown resident Eddie Mitchell. After radiation and chemo, his melanoma disappeared, then returned -- spreading to his spleen and liver. His last resort was Keytruda.
"I have to admit, I was very skeptical at first, because I'd already been through one," Mitchell said. "And I was like, 'well let's just do whatever, and we'll see what happens.' But, in the back of my mind, I was like, 'Well this might not work either.'"
But it did. Within 6 months, Eddie also went from stage 4 to cancer-free.
"It really does blow your mind to think that, but for a little bit of time, the outturn could have been completely different," said Mitchell.
Time -- because, while the concept of immuno-therapy has been around for decades, researchers only recently discovered that immune cells can shut down. But new drugs like Keytruda and Opdivo keep that from happening. Whereas, just three or four years ago, 5-percent survived melanoma, that number is now near 70-percent. And that's just the beginning.
"It's led now to an explosion. And I would predict in five years, we're going to see a 25-percent reduction in cancer-related deaths in the United States as a result of it," Dr. Chesney said.
The James Graham Brown Cancer Center is developing a new drug to boost the fight against lung cancer, among which Kentucky holds the highest death rate in the nation. It's hoped that drug will increase the current 25-percent response among lung cancer patients to 50-percent or more.
"So the idea is to combine that drug that was developed here with these immune checkpoint inhibitors and see if we get a synergistic interaction and we can overcome the 40-percent response rate and make it a 100-percent response rate, and that's the holy grail," said Dr. Chesney. "With what I'm seeing today in melanoma and lung cancer, certainly with these immune checkpoint inhibitors, we're talking about 10 years."
But one big key to that, Dr. Chesney says, is increasing the participation in clinical trials, which stands at just 10-percent. He puts much of the blame for that on doctors, who he says are putting money above their patients.
"Clinical trials take a lot of time, and time is money. And the physicians can make a lot more money if they don't participate in clinical trials. But it's about doing the right thing," he said. "I don't believe a patient with any kind of cancer should die without having been treated with one of these agents."
The James Graham Brown Cancer Center currently has a long list of trials going on with these new drugs, involving several types of cancer. You don't have to have your doctor's OK to be a part of these trials.
One of the best parts of Keytruda and Opdivo are the minimal side effects.
The patients we talked with say they mainly felt fatigue for a day or two after their treatments.
For more information on the trials, click here.
Copyright 2016 WDRB News. All rights reserved.
I'm rooting for you and I say a prayer for you every day Krakonos!
Loofman
Exwannabe...
Sorry you are so upset about the current state of PPHM. You are one of the fine gentlemen that I feel has contributed significantly to our understanding of the science and the process of bringing a drug through the trial process. I hope you will continue to share your level opinion here. I know how hard it is not to allow our emotions enter into our investment decisions. My decision to invest 6 figures into this company has played largely many times into my opinions here, yet I must remind myself it was my own decision to make this investment.
Thank you for all you have contributed so far.
Loofman
It's time to be compassionate human beings. Every single person who invested in PPHM knows perfectly well the risk involved in what they we're investing in. There are no 100% for sure investments. One of our worst enemies in investing is ourselves. We fail to reason with the realities that presents themselves to us. Unfortunately, too many of us look to others to make significant financial decisions. It still comes down to each one of us. We control our own destiny. So, with this I say God's not dead and neither is PPHM!
Jmo
Loofman
Historical adjusted PPHM closing prices (real price adjusted for splits)
Highest = $70.00 on March 7, 2000
Lowest = .39 cents on March 1, 2016
This equates to a loss from the high to the low of 99.44% in 16 years.
Hardly appears as if our BOD has been truely trying to increase shareholder value!
Maybe it's time for a change? Unfortunately they are the only ones who can affect such change.
Maybe you all can send enough cards, letters, voicemails, phone calls, love notes, and flowers with notes attached to at least think about what their next step might be???
jmo
Loofman
Today's intraday low is the lowest price PPHM has had since March of 2009
Mar 10, 2009 LOW 0.31 CLOSE 0.33
Reason for Halt
LUDP Volatility Trading Pause (PPHMP)
Trading restarted on PPHMP
Trade Halt on PPHMP
So I increase my holdings by a large % and the stock goes down again. Not that I didn't expect it, but I do wonder how it can be valued much less than .39 cents with the assets and cash it has. IMO, it's time for all of us longs to send a roll or two of duct tape to Steve and gang so they can start patching this sinking ship up and quickly!
Jmo
Loofman
Wook...no perception needed. It was clearly stated that Bavi did not fail at it's stated goals. What failed was the test. The parameters were skewed by exceptional numbers in the control arm. What needs to be investigated is not Bavi, but why the control arm had better results than historical norm. That's all I see here.
Jmo
Loofman
Tessi May says we will see some recovery after a few days of knee jerkin' reaction. Then probably a climb back to the sixties with a few puke parties back down to the upper thirties before settling back around sixty. After about 2 months of this, we should see a modest climb back into the .80's with some spikes back to the dollar range by year end. If'n them fellers at PPHM don't ATM, this here stock for the next 9 months, then we might do better. Throw in some big drug addicts at Avid who need a couple of btg fixes and all this might add up to $1.50 by next Spring! Then, thar is them AstroZenica fellers who might want to buys some Bavi fer a coming out party after they does some experimenting and that could git the price up to a hole heap in' $3 by summer 2017. Then, It's cocktail weinie and natielight beer party time at loof's annual squirrel fest.
TAKE THIS SERIOUS LIKE CAUSE TESSI MAY IS NEVER WRONG AND MORE RIGHT THAN MOST OF THEM PPHM FELLERS!!!
Mark them thar words! If'n she ain't write, she will take a 8x10 glossy of herself holdin' nuthin, but her bare jugs! That's a promise!!
Jmo
Love
Loofman
The Biologics License Application (BLA) is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR 601.2). The BLA is regulated under 21 CFR 600 – 680. A BLA is submitted by any legal person or entity who is engaged in manufacture or an applicant for a license who takes responsibility for compliance with product and establishment standards
scotsand...that's great and good. Glad you plan to be here for the next 4 years while that develops (or not).
Good luck with Peregrine until they figure out how to survive.
Jmo
Best regards,
Loofman
Jake...right there with ya! Good thoughts.
Bio...I agree completely with you. It is now imperative that Peregrine partners to survive after two huge failures in 3 years. If they/we have any hope of seeing Bavi getting a real chance to be proven out to help battle cancer and on to approval, financial partnership/buyout must be done. ASAP! Not to do so shows that management cares little about it's responsibilities to its shareholders and the money they've been entrusted with. They need bigger shoulders and more brain power to get to the finish line NOW! Time is not on their side or ours as investors.
I trust that they know all this already.
We as shareholders may never see the days of $30+ a share, but if the company partners with the likes of an Astrazenica, we may possibly see $5-$10 again.
Jmo
Loofman
PS - PEREGRINE...git 'er done NOW!
veeets...you can say that again! I believe...
I need another drink. You hit the nail on the head.
Jmo
Loofman
Concerning PPHM...
I have fully consumed 8 jugs of Korn licker and it didn't help. First time ever.
I guess you get what you get. My brain, my decision, my problem. Mama always told me life is like a box of chocolates....you never know what your going to get. I got the one nobody wants.
Loofman
So I do find it interesting out of aproximately 300mil shares only 11 mil have traded, yet the stock price is down 62%. 5.5 mil sells between .38-.41 and 5.5 mil buys at around .40.
Ok I'm sticking around til the end of the year. Bavi is not dead.
Jmo
Loofman
Amazing that the following was said just over a month ago in a company PR:
“As we wrap up enrollment in the SUNRISE trial, we recognize that we are at an ideal juncture to continue expanding the potential of bavituximab with standard of care and immunotherapy combinations in multiple solid tumor types. Combined with the SUNRISE trial, the new studies we have planned can help solidify the potential of bavituximab in NSCLC while significantly expanding the market opportunity in breast cancer,” said Steven W. King, president and chief executive officer of Peregrine. “Driving our strategy is the goal of further demonstrating that bavituximab can provide therapeutic benefit to available cancer treatments, regardless of whether those are traditional therapies such as chemotherapy and radiation, or the emerging novel class of immuno-oncology agents. In today’s update, it is evident that we are moving aggressively to compile a significant body of clinical evidence to support bavituximab’s utility in multiple cancers and across a range of treatment regimens. By doing so, we hope to optimally position bavituximab for success.”
CP with loving respect...
1. No opportunity to salvage data and just spent $60 mil of shareholder money for a cancelled plll trial.
2. I believe tomorrow and for days to come the share price will be hammered with millions of shares shorted and sold. Without any events to look forward to of significance. We are in stormy waters.
3. There is nothing wrong with Bavi nor is there a nothing right about it. We are back on the ground floor 3 years later.
4. Collaborations are good when there is strong evidence to support them. Now there is none.
5. Clinical trial is nice but now tainted because of lack in trust of past results and lack there of them.
6. While this may not be a CA grade event, it's not going to stop the same loonies who are looking for the next train wreck to sue somebody for something.
Jmo
Loofman
I love the majority of you people! I mean that. There are a lot of good souls here that I've stayed in touch with all these years. Be strong as you can and know there will be a better day to come!
Loofman
I'm certainly drinking enough and it ain't Korn licker. The still blew up with the shack. Now I'm drinking
some cheap 45% brown agave tequila with a dead worm in it that my neighbor down yonder found in a ditch along Lifesabitch Road. Thank God fer friends!
Loofman
In writing this I am trying leave my emotion out of this and express my opinion in a calm rational way. To be short and to the point...
1. Peregrine needs to immediately begin courting suitors for buyout. The buyout could divided into two parts.
a. Bavi for whatever we can get for it. Maybe the equivalent of $2 a share.
b. Sell or spin off Avid for $1.50 - $2 share.
2. Dismantle the current board of directors. Imo, their lack of delivering in terms of share price and positive trial results is clearly detrimental to the ongoing operations and to shareholder value. After all these years at their helm we are in many ways back to zero, with pipeline and have an asset that has value that needs to be made profitable to compensate the longstanding shareholders who have been placing their faith in this management team!
That is all. I think we can get $3-4 bucks for all the pieces if we play our cards quickly and I intelligently.
I am quite open to contrary opinion.
Sad Loofman
And there goes a HUGE piece of Loofman's retirement.
I have nothing more to say but I'm sick.
My heart goes out to all of us who believed.
Loofman
FWIW...we've formed a cup and handle on the 20 day chart.
Maybe a launch pad fer me rocket type vehicle?
jmo
Loofman
You are welcome Threes. I have appreciated your contributions here over these many years.
Hang on tight. I think Tessi May is gettin' close to fueling up the rocket type space vehicle with mass quantities of pure kentucky korn licker!
jmo
Loofman
I'd say more like 150k. Not enough volume there in that burst to justify that many shares purchased. imo
Loofman
IMO, I say have cash on the sideline for further fake outs like this and buy, buy, buy! They want to play, I want to play! Don't set those stop limits unless you have nards the size of mountains!
jmo
Loofman
10%+ drop on less than a 150k shares! Game Playing at it's finest. Love to know who gets away with this stuff!
RRdogs (Jeff's) first post here...
A guiding light for me as an investor in Peregine! Thank you Jeff.
Loofman
This is a first time post from a long time investor/ trader in PPHM.
Bias:
As a firm, we have traded PPHM since it was called TCLN and we were there for the "mythological" move to $15/ share in 2000 and for several other moves over 300%. We have taken our losses from time to time but over all have made a great deal of money in PPHM.
We are long side biased. We are never short this stock on balance. IMHO, given the risk and reward in a small biotech with this story, an investor would have to have "mathematical rocks" in his head to be a net short at these levels.
From time to time we have been extremely opposed to mgmt policy and have not been shy about voicing our concerns.
Our great frustration has been that PPHM has yet to complete its mission which would not only make a great deal of money for many long side investors but, might also do a lot of people some real good in a medical sense. Nevertheless, we are always hopeful.
At this moment in time, no matter how actively we trade PPHM, we always maintain a large long side position on balance. We have no proprietary inside information nor do we want any.
.
So much for biases. Readers can view our comments from that perspective.
We have long enjoyed the debates that rage on IHUB and see the merits of both sides of the debate. In addition, we find IHUB has some first rate contributors that are faster to the news than almost any other source and really dig deeply into various sources.
Recently, we have enjoyed the debate on compensation. Of course, IMHO, this board is overpaid. The BOD also appears rampant with cronyism, and to a man has no heavyweight credentials in Govt Contract Procurement (who knows what countless millions have been left on the table), no credentials in domestic biotech universe be it large or intermediate pharma, no int'l credentials, and worst of all no credentials in early stage or late stage partnering and financing. The financing methodology seems to us to be particularly infantile for a company with this much scientific and regulatory strength--- especially after ten years.
We all know that price per share and market cap are fundamentals particularly in a company like PPHM that funds through use of an ATM process from time to time. There are three or four analysts that follow PPHM at various small firms and they do some very sophisticated modeling to determine that PPHM has a present discounted value of between $7.50 and $10 per share. So PPHM is trading somewhere between about a third to a fourth of their own analysts valuation.
We also note that PPHM is trading for only about half of "total paid in capital" which now exceeds $256mm. Worst of all, IMHO, PPHM is trading for what we estimate to be less than 10% of pipeline replacement value. All these cool experimental tests PPHM runs get more and more expensive to duplicate year by year.
Management, has done a fantastic job in some ways, but clearly,
as far as communicating the real value of PPHM to the investment community writ large, they are an unmitigated disaster. We hope for a major strategic shift in the way they communicate immediately as it affects dilution of investor/ owners as well as mgmt owners, and board owners.
If mgmt cannot communicate the true underlying values in PPHM they should shift their strategic thinking about "earlier stage" partnering. There have been a number of early stage partnering deals that have been positive block busters Sure, PPHM may give up some front money but most of that can be made up in milestone payments. There are many ways to accomplish relatively non-dilutive financing without giving away the crown jewels. Two quick examples:
1. PPHM could make a "regional" sale for Japan or Europe in some part of the pipeline such as Cotara or one of the viral products.
Wouldn't a limited loss leader of this sort be better strategically than selling large percentages of the "whole" company at deep discounts. Again, the math is compelling so even the management thinking at PPHM may turn more flexible.
2. PPHM has huge untapped IP with literally hundreds of patents that were painstakingly applied for and the majority of which are not germain to PPHM core programs. If this IP were marketed intelligently to companies that do have special interest in the areas covered IMHO millions of dollars of value could be harvested. You think not?? Well consider the patents covering diagnostics. Dr. Thorpe believes that Bavi which adheres to the cell surface of tumors may lead to the finest three dimensional diagnostic imaging process ever developed. Diagnostic companies make a lot of money. This is an area that could be partnered and in our opinion worth tens of millions of dollars to PPHM, and, an excellent example of hidden value in this stock.
We can think of at least half a dozen other ways to obtain financing without large percentage dilution if mgmt cannot raise the price through better communication. Given the dirth of pipeline at big pharma this is almost a "no brainer" and we believe mgmt will wake up to reality.
All the aforementioned having been said. PPHM appears to be potentially one of the great investment opportunities of our time "even if diluted another 30-50%".
"Watch the feet":
When heavyweights move to a small company, pay close attention to that small company. In my investment group, we are particularly impressed with the addition of Dr. Menander to the PPHM regulatory team. Combined, Dr. M and Dr. G have directly
supported the regulatory process for 32 drugs through the FDA.
If you add the total revenue produced by these drugs it is a mathematical fact --not opinion-- that little PPHM now has one of the top regulatory teams in the country, if not "the" top team, bar none and inclusive of big pharma. And that means the regulatory team "LOVES THE PIPELINE AT PPHM" or why else would they be at this little company.
The best analogy I can think of is, if you add Carmelo Anthony to Amare Stoudemire you are likely to get "more scoring". It doesnt even matter if drugs in the pipeline are approved or not, though, of course it would be much better if the drugs become commercial. (IMHO) PPHM is likely to rise 500 -1000% just on getting into Phase IIIs and partnering. I have complete confidence that Dr. M and Dr. G can move the pipeline into phase IIIs and perhaps with SPAs as well for added benefit in reasonable time. (Some folk think they can accelerate even faster than that but, let's leave that discussion alone for the time being.)
We have observed this phenomenon in many biotech investments. In one of our own early stage biotech adventures our investment rose twenty times over before being finally rejected at the FDA. IMHO, shareholders in PPHM will have ample time, from much higher levels, to decide what percentage of their investment with which to take FDA risk. (By the way, there is always FDA risk no matter how good something looks. The FDA can always say "We like your data and safety but just to be sure go do another couple of years of testing.)
Nevertheless, it is our opinion that PPHM may do better at the FDA than many biotechs because of Garnick's brilliant strategy using unmet need in the most deadly areas to get PPHM "camels nose under the FDA tent". In addition Dr. G and Dr. M know how to talk to FDA and how to set up trials in the most efficient way and they understand the power of an SPA. So again we remain hopeful.
Dr. M's arrival at PPHM suggests some other thoughts as well. IMHO, she has a following not only in the U.S. but, also in Europe, not only corporately but, investment buy side as well. Following the time line, Dr. M comes a year or two behind Dr. G and her arrival is "confirmation" at the highest level of his vision.
These two regulatory experts do not make hasty or rash or emotional decisions. They are late stage in their careers. To continue the basketball analogy, they move where they think they can win. They are very sophisticated about advancing science in both virology and oncology, they look for pathways where they have a high degree of "probability" of regulatory success in a reasonable time frame.
From an investment perspective, these doctors go where they can make option fortunes should they be successful. More important, from the point of view of the outside PPHM investor, they do their homework and diligence. THEY WOULD NOT GO TO ANY COMPANY THEY FELT HAD TAINTED SCIENCE, WAS MALFEASANT OR NON COMPLIANT IN CORPORATE REGULATION, AND THEY WOULD NOT GO ANYPLACE THEY WERE NOT CONVINCED COULD EASILY FINANCE THE JOURNEY OR PARTNER THE JOURNEY. The implied diligence and track record of Dr. M and Dr. G. give me more confidence in my own diligence.
Besides PPHM's regulatory tandem, there are many other "highly informed and scientific" third party affirmations of PPHM pipeline . Most recent of these is the IST at Chapel Hill.
Also among the "highly informed" people that think there is merit in PPHM research, IMHO, are the regulators at the FDA who are kept meticulously informed of developments and that green light much of the pipeline going forward.
In conclusion:
Though there is always a "probability spectrum of outcome" as PPHM or any biotech approach later stages of their pipeline, we believe there is a high probability that PPHM capitalization may move many times higher before the first FDA decision is rendered.
Buffett has an adage -- "It's better to be generally right than precisely wrong". I think people on this message board re PPHM know exactly what he is getting at. Even if certain facts are negative, we have to properly "weight" each fact within the entire argument.
Lastly, I propose a small "thought experiment". Close your eyes and imagine you are the man people on this board love to hate the most. That's right -- imagine you are Eric Swartz. Keep your eyes closed and imagine you are long, free and clear, high and dry , over 3mm shares of PPHM.
If PPHM goes to ten, your position is worth $30mm. This is easy to imagine since 10 would only be about 650mm market cap and PPHM has been at 500mm cap when it had nothing but BS. Further imagine you continue to hold the bulk of your stock and it goes to a hundred after several FDA green lights and new partners. Not impossible. If there were 100mm shares at 100 that would be a market cap of 10 billion --not an impossible number for a successful biotech company. Really imagine this. You would be one of the richest people in the country worth over $300,000,000.
Now, my bet is that even the "message board despised" Eric S will understand as "you" in the thought experiment would understand that for these stakes:
1. It's better to be squeaky clean, quiet, and regulatory compliant than to be dishonest.
2. Less dilution is better than more dilution.
3. Better communication of value to the investment community is superior to obtusely scientific communication.
4. Since the board of directors doesn't have a lot of depth, I better bring in the best people I can to help me with deal strategy.
5. Sometimes an earlier stage deal at less than top dollar in a "small part of the pipeline" might be superior to selling large percentages of the "whole company" at deep discount to real value.
6. That an improved balance sheet is better than a "going concern"
problem with the accountants.
Sooner or later these tensions will be adjusted. I want to take advantage sooner and hopefully profit later. That's just my opinion.
I wish everyone on the message board good luck and look forward to further "debunking" debate.
Rest in peace Jeff. Your contributions will be missed greatly.
Y'all let me know when you think it is a good time to move that PPHM rocket type space vehicle back onto the shoot off pad. I got Tessi May lubricatin' parts all over anticipating a signal that it's time to git it up!
Jmo
Loofman
I just want to say that I have heartfelt hope for Bavi to be successful. I know many who read this thread are directly impacted by cancer in some shape or form. Either it be some of us who post here, family members or friends, so many have had to face this ugly unrelenting beast. I have prayed for many of you and I have prayed for the men and women who work for Peregrine to be given the skills and knowledge to bring healing to those in need. While it would be wonderful to make a significant gain on my investment, I believe the biggest gain of all would be the success of Bavi in extending lives. This is the most important thing my investment can do, imo.
I am sober tonight. Tessi May agrees with me. Good night my PPHM friends.
Loofman
Sharing the Bavituximab video
I have posted the Bavituximab video from Peregrine's webside on my Facebook page. Since I have nearly 300 good friends, i felt this might be a good way to bring awareness about the company's lead candidate in the rapidly immerging field of imunology, especially since the subject is now highly visible in the news today. I suggested the video be shared by those who find it of interest so that others may find some much needed hope in healing options for cancer. Will this bring grassroots awareness to Bavi? I hope so...it's worth getting the message out there, imo.
jmo
Loofman
Jim...
I've fallen and I cain't git up. I've been down so long I just gots to sit here and wait. Ain't no other option, imo.
Loofman
Ya know...I'm at that point with PPHM where I feel like I've been standing in line on Black Friday at Walmart, hoping to get that 60" 4K TV for $128.99! It feels like I got in line to be one of the first 100 to get one, but I've been standing in line for 8 years. I thought I brought enough Korn licker, but I've had to share a bunch with a few of the other line standees. I am worried that I will run out before the doors open.
I need a shower and a hot meal real bad like.
Jmo
Loofman
Only .42 cents from hitting PPHM's 10 year low.
While remaining positive about potential events...l do think it's worthy to mention that a majority of CEO's would have lost their jobs with this kind of share price performance. But, I remind myself this is biopharm and force myself to focus on the future. Time fer another jug.
jmo
Loofman